Macrophage depletion increases the safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo

Gene Therapy
A I KuzminR C Eisensmith

Abstract

The consequences of macrophage depletion achieved by intravenous infusion of liposome-encapsulated clodronate (dichlormethylene diphosphonate (Cl2MDP)) on adenovirus-mediated transfer of a recombinant human alpha 1-antitrypsin (hAAT) gene were examined in 12-14-week-old male Balb/c mice. The levels of hAAT expression following tail vein infusions of 10(9) p.f.u. of Ad.RSV-hAAT were approximately four-fold higher in macrophage-depleted animals than in control animals pretreated with liposome-encapsulated phosphate-buffered saline (PBS). Clodronate pretreatment also significantly increased the survival of animals injected with high doses of viral vector. Long-term studies performed in animals receiving tail vein infusions of the adenoviral vector also indicated that clodronate pretreatment significantly attenuated the rapid loss of transgene expression usually observed in immunocompetent animals. These findings indicate that the depletion of macrophages before adenovirus-mediated gene transfer may increase the transduction efficiency and reduce the rate of immunologic elimination of the adenovirally transduced cells, thereby increasing the persistence of transgene expression in immunocompetent animals.

Citations

Oct 26, 1999·Clinica Chimica Acta; International Journal of Clinical Chemistry·A JózkowiczA Dembińska-Kieć
Apr 20, 2004·Critical Reviews in Oncology/hematology·Frederik H E SchagenRob C Hoeben
Oct 21, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jan-Michael PrillFlorian Kreppel
Oct 19, 2005·Gene Therapy·R AlbaM Chillon
Feb 3, 2005·Human Gene Therapy·Daniel A Muruve
Feb 11, 2005·Human Gene Therapy·Donna J Palmer, Philip Ng
Oct 27, 1999·Proceedings of the National Academy of Sciences of the United States of America·N MorralA L Beaudet
Aug 15, 2014·Gene Therapy·P PiccoloN Brunetti-Pierri
Sep 1, 2005·Alcoholism, Clinical and Experimental Research·Eduardo KarahanianYedy Israel
Dec 2, 2009·The American Journal of Pathology·Frank JacobsBart De Geest
Apr 28, 2005·Surgery·Alexander L ShifrinSteven E Raper
Apr 24, 2014·Liver International : Official Journal of the International Association for the Study of the Liver·Pilar AlzugurenRuben Hernandez-Alcoceba
Oct 8, 2011·International Journal of Pharmaceutics·Z MohammadiM Rafiee Tehrani
Jun 23, 2009·Virology·Shanna L AshleyKatherine R Spindler
Apr 24, 2002·Pulmonary Pharmacology & Therapeutics·J VadolasP A Ioannou
Aug 6, 2002·Molecular Therapy : the Journal of the American Society of Gene Therapy·John MarshallSeng H Cheng
Feb 8, 2003·Molecular Therapy : the Journal of the American Society of Gene Therapy·Gudrun SchiednerStefan Kochanek
Feb 28, 2002·Molecular Therapy : the Journal of the American Society of Gene Therapy·Xiao-Kang LiTorayuki Okuyama
Aug 23, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jan SnoeysBart De Geest
Oct 4, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Elanchezhiyan ManickanAndrew P Byrnes
Mar 29, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·A I KuzminR C Eisensmith
Jun 21, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Nicola Brunetti-PierriPhilip Ng
Mar 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Enrique CasadoWaleed Arafat
Aug 31, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Julien CrettazGloria González-Aseguinolaza

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.